Skip to main content

Advertisement

SpringerLink
Log in

Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance

  • Laboratory Investigation - Human/Animal Tissue
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Temozolomide (TMZ) is the most effective chemotherapeutic agent for glioblastoma (GBM). Resistance to this methylating agent is linked to DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT). However, in recent studies MGMT status was not completely accurate as a predictor of TMZ response in GBM, suggesting other mechanisms of resistance. As part of an effort aimed at discovery of genes involved in TMZ resistance in GBM, the expression of CD74 was evaluated in GBM patient samples and the influence of CD74 on TMZ response was evaluated in GBM tumor models. Reverse transcription-polymerase-chain reaction (RT-PCR) demonstrated differential expression of CD74 mRNA among the GBM xenografts; 8 of 20 (40%) expressed CD74 mRNA. In a preliminary evaluation of whether CD74 expression might influence TMZ response, CD74 mRNA expression levels were inversely associated with in vivo TMZ resistance in 20 GBM xenograft lines (median survival 122 vs. 62.5 days; r = −0.48, P = 0.032). In follow up to this observation, CD74 shRNA knock down in U87 cells significantly suppressed in vitro proliferation and increased TMZ sensitivity as compared to a non-specific control shRNA. Consistent with an effect on proliferation and survival, silencing of CD74 by shRNA was associated with reduced Akt and Erk1/2 activation in response to stimulation by CD74 ligand macrophage-migration inhibition factor (MIF). Lastly, expression of CD74 protein was assessed in patient samples [nine anaplastic astrocytoma (AA), and 62 GBM] by immunohistochemistry, and appreciable expression was observed in 28% of samples. Collectively, these findings suggest that CD74 is expressed in a subset of high grade gliomas and may contribute to TMZ resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Stumptner-Cuvelette P, Benaroch P (2002) Multiple roles of the invariant chain in MHC class II function. Biochim Biophys Acta 1542:1–13

    Article  CAS  PubMed  Google Scholar 

  2. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197:1467–1476

    Article  CAS  PubMed  Google Scholar 

  3. Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L, Becker-Herman S, Berrebi A, Shachar I (2006) Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107:4807–4816

    Article  CAS  PubMed  Google Scholar 

  4. Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Luscher B, Bernhagen J (2007) Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26:5046–5059

    Article  CAS  PubMed  Google Scholar 

  5. Datta MW, Shahsafaei A, Nadler LM, Freeman GJ, Dorfman DM (2000) Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol 8:210–215

    Article  CAS  PubMed  Google Scholar 

  6. Meyer-Siegler KL, Leifheit EC, Vera PL (2004) Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 4:34

    Article  PubMed  Google Scholar 

  7. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Iwashige H, Aridome K, Hokita S, Aikou T (2001) Invariant chain expression in gastric cancer. Cancer Lett 168:87–97

    Article  CAS  PubMed  Google Scholar 

  8. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS (2001) Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 158:1639–1651

    CAS  PubMed  Google Scholar 

  9. Ioachim HL, Pambuccian SE, Hekimgil M, Giancotti FR, Dorsett BH (1996) Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Am J Surg Pathol 20:64–71

    Article  CAS  PubMed  Google Scholar 

  10. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164–176

    Article  CAS  PubMed  Google Scholar 

  11. Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN (2009) Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol 92:23–31

    Article  CAS  PubMed  Google Scholar 

  12. Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN (2009) Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys 75:212–219

    CAS  PubMed  Google Scholar 

  13. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma.[see comment]. N Engl J Med 352:997–1003

    Article  CAS  PubMed  Google Scholar 

  14. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48:403–407

    Article  PubMed  Google Scholar 

  15. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197

    Article  PubMed  Google Scholar 

  16. Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J (2007) Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo) 47:341–349 (discussion 350)

    Article  Google Scholar 

  17. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM (2004) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 10:6606–6611

    Article  CAS  PubMed  Google Scholar 

  18. Shih L, Ong GL, Burton J, Mishina D, Goldenberg DM, Mattes MJ (2000) Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice. Cancer Immunol Immunother 49:208–216

    Article  CAS  PubMed  Google Scholar 

  19. Mark T, Martin P, Leonard JP, Niesvizky R (2009) Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 18:99–104

    Article  CAS  PubMed  Google Scholar 

  20. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM (2007) CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 13:5556s–5563s

    Article  CAS  PubMed  Google Scholar 

  21. Chang CH, Sapra P, Vanama SS, Hansen HJ, Horak ID, Goldenberg DM (2005) Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 106:4308–4314

    Article  CAS  PubMed  Google Scholar 

  22. Stein R, Qu Z, Cardillo TM, Chen S, Rosario A, Horak ID, Hansen HJ, Goldenberg DM (2004) Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 104:3705–3711

    Article  CAS  PubMed  Google Scholar 

  23. Mandal S, Curtis L, Pind M, Murphy LC, Watson PH (2007) S100A7 (psoriasin) influences immune response genes in human breast cancer. Exp Cell Res 313:3016–3025

    Article  CAS  PubMed  Google Scholar 

  24. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K (2003) Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 1:362–375

    CAS  PubMed  Google Scholar 

  25. Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R, Bernhagen J (2006) Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18:688–703

    Article  CAS  PubMed  Google Scholar 

  26. Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, Noble P, Knudson W, Bucala R (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25:595–606

    Article  CAS  PubMed  Google Scholar 

  27. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683–2710

    Article  CAS  PubMed  Google Scholar 

  28. Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G, Schlegel J (2003) Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol 162:11–17

    CAS  PubMed  Google Scholar 

  29. Munaut C, Boniver J, Foidart JM, Deprez M (2002) Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression. Neuropathol Appl Neurobiol 28:452–460

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH grant to J.N.S. (RO1 CA127716, P50 CA 108961) and Mayo Brain SPORE Career Development award to G.J.K. (P50 CA 108961).

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Mayo Clinic, 200 First Street NW, Rochester, MN, 55905, USA

    Gaspar J. Kitange, Brett L. Carlson, Mark A. Schroeder & Jann N. Sarkaria

  2. Department of Biostatistics, Mayo Clinic, Rochester, MN, USA

    Paul A. Decker, Bruce W. Morlan, Wenting Wu & Karla V. Ballman

  3. Department of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA

    Caterina Giannini

Authors
  1. Gaspar J. Kitange
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brett L. Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark A. Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul A. Decker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bruce W. Morlan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wenting Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Karla V. Ballman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Caterina Giannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jann N. Sarkaria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gaspar J. Kitange.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kitange, G.J., Carlson, B.L., Schroeder, M.A. et al. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. J Neurooncol 100, 177–186 (2010). https://doi.org/10.1007/s11060-010-0186-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0186-9

Keywords

Search

Navigation